A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape

We wanted to implement an NGS strategy to globally analyze hereditary cancer with diagnostic quality while retaining the same degree of understanding and control we had in pre-NGS strategies. To do this, we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes. We imp...

Full description

Saved in:
Bibliographic Details
Published inScientific reports
Main Authors Castellanos, Elisabeth, Gel, Bernat, Rosas, Inma, Tornero, Eva, Santín, Sheila, Pluvinet, Raquel, Velasco, Juan, Sumoy, Lauro, Valle, Jesús del, Perucho, Manuel, Blanco Guillermo, Ignacio, Navarro, Matilde, Brunet, Joan, Pineda Riu, Marta, Feliubadaló i Elorza, Maria Lídia, Capellá, G. (Gabriel), Lázaro García, Conxi, Serra, Eduard
Format Journal Article
LanguageEnglish
Published Nature Publishing Group 04.01.2017
Subjects
Cancer
Cribratge genètic
Càncer
Diagnosis
Diagnòstic
Genetic screening
Neurofibromatosi
Neurofibromatosis
Online AccessGet full text

Cover

More Information
Summary:We wanted to implement an NGS strategy to globally analyze hereditary cancer with diagnostic quality while retaining the same degree of understanding and control we had in pre-NGS strategies. To do this, we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes. We improved bait design, tested different NGS platforms and created a clinically driven custom data analysis pipeline. The I2HCP panel was developed using a training set of hereditary colorectal cancer, hereditary breast and ovarian cancer and neurofibromatosis patients and reached an accuracy, analytical sensitivity and specificity greater than 99%, which was maintained in a validation set. I2HCP changed our diagnostic approach, involving clinicians and a genetic diagnostics team from panel design to reporting. The new strategy improved diagnostic sensitivity, solved uncertain clinical diagnoses and identified mutations in new genes. We assessed the genetic variation in the complete set of hereditary cancer genes, revealing a complex variation landscape that coexists with the disease-causing mutation. We developed, validated and implemented a custom NGS-based strategy for hereditary cancer diagnostics that improved our previous workflows. Additionally, the existence of a rich genetic variation in hereditary cancer genes favors the use of this panel to investigate their role in cancer risk.
ISSN:2045-2322
2045-2322